Analysis highlights regulatory complexities of stem cell-based human embryo models, suggesting caution in oversight frameworks.
Stem cell-based human embryo models (SCBEMs), generated in vitro from stem cells, currently exist outside the scope of regulatory frameworks that govern in vitro embryo research in most jurisdictions. A widely discussed proposal suggests using a "Turing test" framework, whereby regulatory oversight is triggered if a SCBEM is found to be “equivalent” to a human embryo. In this paper, we argue that such a proposal faces two major complications. First, sophisticated laboratory techniques such as trophoblast replacement allow researchers to manipulate normal embryogenesis, obscuring whether a given SCBEM meets embryo-like thresholds. Second, attempts to assess SCBEMs’ developmental potential—especially through non-human analogues—rest on tenuous epistemic assumptions that may not align with human-specific developmental trajectories. Given SCBEMs’ potential manipulability and uncertain biological and potentiality benchmarks, we argue that reliance on equivalence-based frameworks alone is highly problematic. We conclude by urging a cautious, flexible approach that recognizes both the scientific promise of SCBEMs and the normative need to prevent the circumvention of regulatory safeguards.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: